搜索
CorMedix Inc
CRMD添加自选
8.750USD
+0.280+3.31%
收盘 07/02, 13:00（美东）报价延迟15分钟
686.45M总市值
3.60市盈率 TTM
关键数据
8.550今开
8.840最高
1.04M成交量
3.60市盈率 TTM
49.75市盈率动
--股息TTM
1.33%换手率
8.470昨收
8.420最低
6.80M成交额
亏损市盈率静
1.57市净率
0.00%股息率 TTM
37.51%ROA
17.43052周最高
0.84量比
-17.93M净利润
78.40M总股本
2.4327每股收益TTM
1.46Beta
65.59%ROE
6.12552周最低
4.96%振幅
82.50%毛利率
686.45M总市值
0.94回报/风险
3.10%风险率
TradingKey CorMedix Inc股票评分
单位: USD 更新时间: 2026-07-02操作建议
CorMedix Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在药品行业排名50/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价15.20。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
CorMedix Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
CorMedix Inc亮点
亮点风险
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值3.60，处于3年历史高位
机构减仓
最新机构持股43.28M股，环比减少30.09%
查克·罗伊斯持仓
明星投资者查克·罗伊斯持仓，最新持仓市值1.52M
分析师目标
根据
5
位分析师
买入
评级
15.200
目标均价
+98.95%
涨幅空间
CorMedix Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CorMedix Inc简介
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
公司代码CRMD
公司CorMedix Inc
CEOTodisco (Joseph)
网址https://cormedix.com/
相关品种
热门品种
常见问题
CorMedix Inc(CRMD)的当前股价是多少？
CorMedix Inc(CRMD)的当前股价是 8.75。
CorMedix Inc的股票代码是什么？
CorMedix Inc的股票代码是CRMD。
CorMedix Inc股票的52周最高点是多少？
CorMedix Inc股票的52周最高点是17.43。
CorMedix Inc股票的52周最低点是多少？
CorMedix Inc股票的52周最低点是6.12。
CorMedix Inc的市值是多少？
CorMedix Inc的市值是685.96M。
现在CorMedix Inc(CRMD)的股票是买入、持有还是卖出？
根据分析师评级，CorMedix Inc(CRMD)的总体评级为买入，目标价格为15.20。
CorMedix Inc(CRMD)股票的每股收益（EPS TTM）是多少
CorMedix Inc(CRMD)股票的每股收益（EPS TTM）是2.26。